Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic

Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab

(2021) Doran Ksienski et al.   Translational Lung Cancer Research

Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

(2021) Kartik Sehgal et al.   JAMA Network Open

MA03.08 Impact of COVID-19 Pandemic in the Diagnosis and Prognosis of Lung Cancer

(2021) R. Reyes et al.   Journal of Thoracic Oncology

Severity of COVID-19 in patients with lung cancer: evidence and challenges

(2021) Antonio Passaro et al.   Journal for ImmunoTherapy of Cancer

Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study

(2021) Sheena Bhalla et al.   LUNG CANCER

Telemedicine for cancer patients during COVID-19 pandemic: between threats and opportunities

(2020) Ronaldo Elkaddoum et al.   Future Oncology

Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features

(2020) Samantha Ellis et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial

(2020) Gary Middleton et al.   Lancet Respiratory Medicine

Managing cancer patients during the COVID-19 pandemic: An ESMO Interdisciplinary Expert Consensus

(2020) G. Curigliano et al.   ANNALS OF ONCOLOGY

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

(2020) Marina Chiara Garassino et al.   LANCET ONCOLOGY

Changes in Lung Cancer Treatment as a Result of the Coronavirus Disease 2019 Pandemic

(2020) Arielle Elkrief et al.   JAMA Oncology

Lung cancer control in the UK hit badly by COVID-19 pandemic

(2020) Elizabeth Gourd   LANCET ONCOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE